Navigation Links
China Pharma Holdings, Inc. to Present at Two Upcoming U.S. Investor Conferences
Date:11/4/2008

HAIKOU CITY, China, Nov. 4 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), a specialty pharmaceutical company which develops, manufactures, and markets its products in China, today announced that senior management will present a corporate overview at two upcoming U.S. conferences.

-- Rodman and Renshaw's Annual Global Investment Conference (Asia and

Growth Track) will be held November 10-12, 2008 at the New York Palace

Hotel in New York City, New York. The Company's presentation will take

place on Monday, November 10th at 5:20pm ET in Henry Salon (5th Floor).

-- Roth Capital's "China Comes to Vegas" conference will be held November

19-21, 2008 at the Wynn Hotel in Las Vegas, Nevada. The Company's

presentation will take place on Friday, November 21st at 9:30am ET in

Palmer 2 - Track 2.

President and CEO, Ms. Zhilin Li, and CFO, Mr. Xinhua Wu, will attend and are available for one-on-one meetings during both conferences to highlight China Pharma Holding's current product portfolio, development pipeline, research and development platform, recent financial highlights and growth strategy.

Ms. Li commented, "I am delighted to visit the US and meet with investors and analysts. I consider these conferences a great opportunity to listen to their ideas, develop mutual understanding, and raise China Pharma's profile in the US. Our goal of this trip is to better understand the US capital markets in order to improve our communications and performance for shareholders."

A live audio webcast of China Pharma Holding's presentation at Roth Capital's conference will be available at http://www.wsw.com/webcast/roth18/cphi.ob and accessible for 90 days following the presentation. Please log on 15 minutes prior to the presentation to download any necessary materials.

For more information on Roth Capital's "China Comes to Vegas" Conference, dedicated to Chinese-based, U.S. listed companies, please visit http://www.roth.com .

For more information on Rodman & Renshaw's Annual Global Investment Conference, featuring Steel, Metals & Mining, Energy, Healthcare, Asia & Growth and SPACs Tracks, please visit http://www.rodmanandrenshaw.com/conferences .

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a biopharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost- effective, high margin business model is driven by market demand and supported by 8 scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding distribution network across more than 29 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Bio-pharmaceutical Co., Ltd (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .

Safe Harbor Statement

Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For further information, please contact:

China Pharma Holdings, Inc.

Diana Huang

Tel: +86-898-6681-1730

Email: hps@chinapharmaholdings.com

The Ruth Group

Sara Ephraim

Tel: +1-646-536-7002

Email: sephraim@theruthgroup.com


'/>"/>
SOURCE China Pharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Yingxia to Present at Roth China Comes to Vegas Conference
2. PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress
3. Sinovac Named to Deloitte Technology Fast 50 China
4. Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China
5. China Medical Technologies Announces Reporting Dates for the September Quarter Results and Addresses Investor Inquiries
6. China Yingxia to Present at Rodman & Renshaw Annual Global Investment Conference
7. China Pharma Holdings, Inc. Appoints The Ruth Group
8. CFO of China Yingxia Emphasizes Growth in Organic and Health Food Segment in Interview by The Wall Street Transcript
9. Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of Chinas Ministry of Science and Technology
10. China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million
11. China Bio Energy Holdings Group Announces Financing and Exercise of Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... TORONTO , Nov. 30, 2016 /PRNewswire/ - Portage ... Canadian Securities Exchange: PBT.U), is excited to announce ... company focused on developing preclinical ophthalmology assets through ... a potent anti-inflammatory created by Portage Pharmaceuticals Limited ... patients with ocular surface and anterior segment diseases. ...
(Date:11/30/2016)... , Nov. 30, 2016 /PRNewswire/ -  Equicare Health ... solutions, has been recognized as one of the top ... an annual international listing that distinguishes the top digital ... pushed a great step forward this year continually upgrading ... our own customer base and team," says Len ...
(Date:11/30/2016)... 2016   Merck , ein führendes ... einer Reihe von Vereinbarungen mit Evotec AG ... Screeningleistungen für Mercks Palette genetischer Reagenzien wie ... diese Bibliotheken in Kombination mit Evotecs Expertise ... zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader in small-molecule cocrystal ... the latest FDA guidance on pharmaceutical cocrystals as drug substance . The ... , The event follows the successful November 15th event that took place in ...
Breaking Biology Technology:
(Date:11/17/2016)...  AIC announces that it has just released a new white paper authored by ... plus high speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can ...
(Date:11/14/2016)... CLARA, Calif. , Nov. 14, 2016 ... the biometric identification market, Frost & Sullivan ... Frost & Sullivan Award for Visionary Innovation ... player in the biometric identification market by ... multi-modal verification solution for instant, seamless, and ...
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
Breaking Biology News(10 mins):